Skip to main content

Table 1 Demographics and clinical characteristics

From: Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway

 

Overall

N = 78,574

Patients with prior mAb usea

N = 26,656

Patients without prior mAb usea

n = 51,918

Demographics

 Age, mean (SD)

46.7 (13.3)

47.0 (12.8)

46.5 (13.5)

 Female sex, n (%)

68,631 (87.4%)

23,319 (87.5%)

45,312 (87.3%)

Index payer type, n (%)

 Commercial

50,607 (64.4%)

17,002 (63.8%)

33,605 (64.7%)

 Discounts/coupons

16,118 (20.5%)

5,234 (19.6%)

10,884 (21.0%)

 Medicaid

7,973 (10.2%)

2,955 (11.1%)

5,018 (9.7%)

 Cash

2,997 (3.8%)

1,134 (4.3%)

1,863 (3.6%)

 Medicare

873 (1.1%)

329 (1.2%)

544 (1.1%)

Prescriber for index medication, n (%)

 Neurologist

37,375 (47.6%)

13,790 (51.7%)

23,585 (45.4%)

 Nurse practitioner/ physician assistant

23,915 (30.4%)

8,553 (32.1%)

15,362 (29.6%)

 Primary care physician

11,719 (14.9%)

2,401 (9.0%)

9,318 (18.0%)

 Pain specialist

1,194 (1.5%)

479 (1.8%)

715 (1.4%)

 Other

4,371 (5.6%)

1,433 (5.4%)

2,938 (5.7%)

Charlson comorbidity index score, n (%)

 0

57,871 (73.7%)

19,770 (74.2%)

38,101 (73.4%)

 1

12,356 (15.7%)

4,174 (15.7%)

8,182 (15.8%)

 2

5,062 (6.4%)

1,665 (6.3%)

3,397 (6.5%)

 3 + 

3,285 (4.2%)

1,047 (3.9%)

2,238 (4.3%)

Most frequent comorbidities (> 5% of patients), n (%)

 Anxiety

14,271 (18.2%)

4,994 (18.7%)

9,277 (17.9%)

 Hypertension

13,792 (17.6%)

4,538 (17.0%)

9,254 (17.8%)

 Depression

11,429 (14.6%)

4,335 (16.3%)

7.094 (13.7%)

 Asthma

5,513 (7.0%)

1,986 (7.5%)

3,527 (6.8%)

  1. mAb monoclonal antibody, SD standard deviation
  2. a Prior mAb (erenumab, galcanezumab, fremanezumab) use was evaluated during the 6-month period prior to the index date